|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines
Datamonitor, Oct 2010, Pages: 342
Introduction
Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that could reach $3.4 billion in infants and adults across the US and 5EU by 2019, leaving only marginal roles for its competitors. The commercial opportunity for MenACWY conjugate vaccines will largely remain restricted to the US, while a broad MenB vaccine could achieve blockbuster status.
Features and benefits
- In-depth analysis of market dynamics for pneumo-and meningococcal vaccines across US, 5EU and Japan, supported by insights of key opinion leaders
- Population-based 10-year sales forecasts for currently available brands and late-stage pipeline vaccines in the US and 5EU.
- Epidemiology section discussing key population trends and epidemiological features of pneumo- and meningococcal disease in the seven major markets
- Thorough assessments of key marketed vaccines and late stage pipeline products.
Highlights
- Datamonitor anticipates the launch of Pfizer’s Prevnar 13 for adults in 2011 and expects the vaccine to quickly replace Merck & Co's Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.4 billion in 2019 across the US and five major EU markets.
- Sales expectations for conjugate MenACWY vaccines are limited in the seven major markets. While the US are unlikely to recommend routine MenACWY vaccination of infants, MenACWY vaccines will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs. Best growth opportunities lie in a meningococcal B vaccine.
- Pneumo- and meningococcal vaccines continue to offer great commercial opportunities due to changing disease epidemiology and extension of age indications. Novartis’ 4CMenB is the most promising pipeline vaccine and expected to quickly reach blockbuster status with possible sales of almost $3 billion in the US and the five major European ma
Your key questions answered
- Identify the market dynamics of pneumo- and meningococcal vaccines, success factors for leading brands and the potential of late stage pipeline
- Obtain full country and product-specific forecasts of currently marketed and pipeline pneumo- and meningococcal vaccines from 2010 to 2019.
- Understand epidemiological trends of pneumo-and meningococcal disease across the seven major markets and their impact on vaccination recommendations
|
|
|
|
